awmsg logo



saxagliptin (Onglyza®)


Reference No. 1975

Publication date:
13/12/2013


Last review date:
20/01/2017

Appraisal information

saxagliptin (Onglyza®) 2.5 mg film-coated tablet
saxagliptin (Onglyza®) 5 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd/AstraZeneca UK Ltd
BNF category: Endocrine system
NMG meeting date: 23/10/2013
AWMSG meeting date: 20/11/2013
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3313
Ministerial ratification: 06/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download